Implantable devices captured half of all medtech funding in a year. Device data platforms captured under 5%, and AcuityMD is nearly the only exception.
Medtech investors are clearly willing to write large checks. Where those checks go reveals a lopsided market that's easy to miss if you're only tracking headline deal sizes.
A 50-point capital share gap between hardware and software
Implantable devices and medical devices attracted the most investor attention in medtech, together accounting for 32 of 52 deals and $2.44B raised over a 12-month period through July 2026, according to New Market Pitch.
Implantable devices alone captured $1.58B across 18 deals, a 50.5% capital share against a 34.6% deal share, a capital-to-deal ratio of 1.46 showing outsized check sizes relative to how often deals actually happen in that category. Device Data Platforms, by contrast, remained underrepresented at just 4.8% of capital despite considerable AI enthusiasm across the sector, with AcuityMD, which builds software specifically for medtech commercialization, standing out as nearly the lone well-funded exception.
Connected diabetes and metabolic monitoring companies raised capital too, but at meaningfully smaller check sizes than implantable-platform rounds, suggesting investors see more competition and less defensibility in that specific software-adjacent corner of the market.
Clinical device risk still commands a premium over software risk
The gap suggests medtech investors still price clinical device risk, will this implant work safely in the body, higher than software risk, even in an environment where AI-driven software is attracting enormous enthusiasm in nearly every other healthcare category. AcuityMD's success as almost the sole well-funded device data platform indicates the market is willing to fund medtech-specific software when it improves device adoption or regulatory throughput directly, rather than when it's a general-purpose data or AI layer without a clear tie back to getting a physical device into more hands.
Whether the AI enthusiasm narrative finally shows up in the funding data
Watch whether Device Data Platforms' 4.8% capital share moves meaningfully in coming reporting periods, since a sustained gap between AI enthusiasm and actual medtech software funding would suggest the category's software opportunity is smaller or harder to capture than the broader AI narrative implies, at least until a second AcuityMD-style breakout proves the exception wasn't a one-off.
